Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul A Reilly

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 15, 2009
Dabigatran etexilate: future directions in anticoagulant treatmentSam Schulman, Paul A Reilly
BMJ (Clinical Research Ed.)|February 4, 2006
One step forward in engaging clinicians in ITMark E Lloyd, Paul A Reilly
Stroke|January 30, 2014
Response to letter regarding article, "Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation"Masatsugu Hori, Michael D Ezekowitz, Paul A Reilly
The New England Journal of Medicine|October 26, 2017
Dabigatran Reversal with IdarucizumabCharles V Pollack, Paul A Reilly, Jeffrey I Weitz
Thrombosis and Haemostasis|December 22, 2011
Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilateSebastian Härtter, Norio Yamamura, Joachim Stangier, et al.
The American Journal of Emergency Medicine|October 7, 2016
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
The American Journal of Medicine|August 30, 2016
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 SubjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
The New England Journal of Medicine|November 5, 2010
Newly identified events in the RE-LY trialStuart J Connolly, Michael D Ezekowitz, Salim Yusuf, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|August 8, 2015
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 ScoreMasatsugu Hori, Taku Fukaya, Eva Kleine, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 26, 2011
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trialMasatsugu Hori, Stuart J Connolly, Michael D Ezekowitz, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|August 15, 2009
Dabigatran etexilate: future directions in anticoagulant treatmentSam Schulman, Paul A Reilly
BMJ (Clinical Research Ed.)|February 4, 2006
One step forward in engaging clinicians in ITMark E Lloyd, Paul A Reilly
Stroke|January 30, 2014
Response to letter regarding article, "Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation"Masatsugu Hori, Michael D Ezekowitz, Paul A Reilly
The New England Journal of Medicine|October 26, 2017
Dabigatran Reversal with IdarucizumabCharles V Pollack, Paul A Reilly, Jeffrey I Weitz
Thrombosis and Haemostasis|December 22, 2011
Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilateSebastian Härtter, Norio Yamamura, Joachim Stangier, et al.
The American Journal of Emergency Medicine|October 7, 2016
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
The American Journal of Medicine|August 30, 2016
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 SubjectsPaul A Reilly, Joanne van Ryn, Oliver Grottke, et al.
The New England Journal of Medicine|November 5, 2010
Newly identified events in the RE-LY trialStuart J Connolly, Michael D Ezekowitz, Salim Yusuf, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|August 8, 2015
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 ScoreMasatsugu Hori, Taku Fukaya, Eva Kleine, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 26, 2011
Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trialMasatsugu Hori, Stuart J Connolly, Michael D Ezekowitz, et al.
Pageof 6